Clinical trials: Magnetic Resonance Imaging Contrast Agents
- Condition Magnetic Resonance Imaging Contrast Agents
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Diagnostic Self Evaluation, Central Nervous System Diseases
Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions
The purpose of this study is to look at the safety (what are the side effects)and efficacy (how well does it work) of Dotarem® when used in taking images of the brain / spine.
- Trial name
- SENTIO (NCT01211873)
- Testing
- Dotarem (gadoterate meglumine), Magnevist (gadopentetate dimeglumine)
- Where
- 52 sites in United States, Argentina and 9 more
- Volunteers
- 416 people
- Sponsor
- Guerbet
Magnetic Resonance Imaging
A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children
In this clinical study a contrast agent for magnetic resonance imaging (MRI), which has already been approved for application in adults, will be investigated in children and adolescents.
- Trial name
- NCT00468819
- Testing
- Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- Where
- 14 sites in Austria, Canada and 2 more
- Volunteers
- 140 people
- Sponsor
- Bayer
Magnetic Resonance Imaging
Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent
This is an open-label, multi-center study involving babies 0-2 months of age who have liver problems (pathology) and need to have their liver and possibly, the bile ducts imaged using magnetic resonance imaging and injection of a…
- Trial name
- NCT02084628
- Testing
- Gadoxetate disodium (Eovist/Primovist, BAY86-4873)
- Where
- 9 sites in United States
- Volunteers
- 1 people
- Sponsor
- Bayer
Contrast Enhancement in Magnetic Resonance Imaging
A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting
This is an observational study, in which data associated with the wastage with the use of Gadavist single-dose vials, as compared to the wastage associated with the use of the Gadavist imaging bulk packages (IBP) used for…
- Trial name
- NCT05350189
- Testing
- Gadobutrol (Gadavist/Gadovist, BAY86-4875)
- Where
- 2 sites in United States
- Volunteers
- 1,602 people
- Sponsor
- Bayer
Cardiovascular Diseases, Microvascular Complications
Non-invasive Microvascular Assessment in Individuals at High Risk of Cardiovascular Disease From the SCAPIS2 Study
Microvascular dysfunction, particularly endothelial dysfunction, is increasingly recognized as a key mechanism underlying various cardiovascular diseases (CVD), including heart failure, ischemic heart disease, atherosclerosis…
- Trial name
- NCT07359768
- Where
- Sweden
- Volunteers
- 900 people
- Sponsor
- HJN Sverige AB/Neko Health
Magnetic Resonance Imaging
Contrast-enhanced MRI in Children 2 Months to <2 Years
The purpose of this study is to determine pharmacokinetics, safety and efficacy of Magnevist in children 2 months to < 2 years of age
- Trial name
- NCT00937391
- Testing
- Gadopentetate dimeglumine (Magnevist, BAY86-6661)
- Where
- 13 sites in United States, Germany
- Volunteers
- 54 people
- Sponsor
- Bayer
Magnetic Resonance Imaging (MRI)
Post-marketing Safety Study in Participants of All Pathologies Who Receive Gadolinium-Based Contrast Agents (GBCAs) for Contrast-Enhanced Magnetic Resonance Imaging (MR) Examination
The purpose of this study is to prospectively collect data on the pattern of use for gadolinium-based contrast agents (GBCAs) in real-life setting with special reference to Clariscan after its commercial launch in Europe and in…
- Trial name
- NCT03455283
- Testing
- Clariscan, Gadolinium-Based Contrast Agents
- Where
- 2 sites in Germany, Norway
- Volunteers
- 2,118 people
- Sponsor
- GE Healthcare
Contrast Enhancement in Magnetic Resonance Imaging, Children
A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric)
Researchers are looking for a better way to help children under the age of 18 with any known or suspected problems scheduled for a "contrast-enhanced" Magnetic Resonance Imaging (MRI).
- Trial name
- NCT05915026
- Testing
- Gadoquatrane (BAY1747846)
- Where
- 34 sites in United States, Argentina and 8 more
- Volunteers
- 105 people
- Sponsor
- Bayer
Magnetic Resonance Imaging, Image Enhancement
Drug Use Investigation of Gadovist.
The objectives of this study are to investigate the safety and effectiveness of Gadovist.
- Trial name
- NCT02540967
- Testing
- Gadobutrol (Gadavist/Gadovist, BAY86-4875)
- Where
- Japan
- Volunteers
- 3,357 people
- Sponsor
- Bayer
Magnetic Resonance Imaging
Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)
The main purpose of this study is to collect data on the way gadobutrol is taken into, moves around, and is eliminated from, the body of children aged 0 to less than 2 years.
- Trial name
- NCT01544166
- Testing
- Gadobutrol (Gadavist, BAY86-4875)
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 44 people
- Sponsor
- Bayer